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Introduction: Dipeptidyl peptidase-4 (DPP-4) inhibitors are widely prescribed for type 2 
diabetes (T2D) and their glycemic control effects are well studied. However, information 
regarding the effects of switching DPP-4 inhibitors is limited, especially in older patients.
Research Design and Methods: We investigated whether switching from linagliptin to 
teneligliptin decreases blood glucose in older (≥65 years) T2D patients. In total, 164 patients 
with T2D who switched from linagliptin to teneligliptin for >12 weeks were included and the 
primary outcome was glycemic changes.
Results: Switching from linagliptin to teneligliptin ameliorated fasting blood glucose (148.1 
± 47.1 to 139.6 ± 43.4 mg/dL), glycated hemoglobin (HbA1c; 7.9 ± 1.3 to 7.5 ± 1.2%), and 
postprandial blood glucose (224.8 ± 77.4 to 205.8 ± 70.8 mg/dL) levels (all P < 0.05). Low- 
density lipoprotein cholesterol concentration was reduced while liver and kidney 
functions were maintained. Subgroup analysis showed that glucose control improved more 
in patients with uncontrolled hyperglycemia (HbA1c > 8.0%) and chronic kidney disease 
(estimated glomerular filtration rate <90 mL/min/1.73m2). Multiple logistic analysis indi-
cated higher baseline HbA1c was the strongest predictor of teneligliptin switching response.
Conclusion: Switching from linagliptin to teneligliptin helps maintain kidney function and 
reduce blood glucose safely in older patients with T2D.
Keywords: dipeptidyl peptidase 4 inhibitor, linagliptin, teneligliptin, type 2 diabetes 
mellitus, older patients, chronic kidney disease
Introduction
Type 2 diabetes (T2D) has become a pandemic and with the aging population, its 
prevalence in older individuals is increasing widely.1 In Korea, the prevalence of 
T2D in older persons (over 65 years) is currently 29.8% and it has been projected 
that by 2060, it will be 40.1% in this population.2 Additionally, T2D and its 
complications are an important cause of morbidity and mortality, leading to psy-
chosocial economic burden.3
Dipeptidyl peptidase-4 (DPP-4) inhibitors are incretin-based drugs that increase 
active endogenous concentrations of glucagon-like peptide-1 (GLP-1), a gut- 
derived hormone that stimulates insulin secretion and delays gastric emptying.4 
DPP-4 inhibitors are associated with a low risk of hypoglycemia and body weight 
gain and have moderate efficacy in blood glucose control; thus, these drugs are one 
of the most commonly prescribed. Many clinical studies have shown that DPP-4 
inhibitors are less likely to cause hypoglycemia than other agents such as 
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sulfonylureas, which have similar potency.5 One of the 
major concerns in choosing antidiabetic medication for 
older patients with T2D is hypoglycemia. Considering 
their pharmacological action mechanism including glu-
cose-dependent effects, DPP-4 inhibitors would be 
a good option for members of older populations with T2D.
Teneligliptin is a novel DPP-4 inhibitor and its chemi-
cal structure comprises five consecutive rings, a phenyl 
ring on the pyrazole, and an S2 extensive subsite, which 
magnifies its sensitivity and potency.6 Several studies have 
shown the clinical efficacy and safety of teneligliptin, both 
as a monotherapy and dual therapy in combination with 
other hypoglycemic drugs including metformin, sulfony-
lureas, and insulin.4,7–10 In addition, teneligliptin can be 
used in patients with T2D who have renal impairment 
without the need for dose reduction.11
Another consideration in choosing anti-hyperglycemic 
agents for older patients with T2D is patient adherence and 
kidney function. Numerous medications are associated 
with poor compliance, especially in older individuals.12 
To maintain the number of medications, switching those 
in the same class would be a useful strategy. Multiple 
DPP-4 inhibitors are now clinically available, wherein 
each has different chemical structure, inhibitory activity 
towards DPP-4, and tissue distribution. However, there is 
limited information regarding the difference in the efficacy 
among DPP-4 inhibitors. To address this important clinical 
question, we conducted an exploratory investigation to 
assess the effect of switching from linagliptin to teneli-
gliptin in older patients with T2D.
Experimental Section
Methods
In this retrospective study, subjects were identified by 
reviewing patient case notes in the electronic medical 
records at Severance Hospital, a tertiary university hospital 
in Korea and Dongsan Medical Center, a tertiary univer-
sity hospital in Korea. We included 164 patients ≥65 years 
old with a history of switching from linagliptin to teneli-
gliptin for glycemic control. T2D was defined according to 
the International Classification of Diseases 10th revision. 
Only those who had not used teneligliptin in the 
preceding year were enrolled. Teneligliptin was used for 
at least 12 weeks.
Patients were excluded if they fulfilled any one of the 
following criteria: (1) kidney transplant or taking immu-
nosuppressant agents; (2) intrinsic renal disease (nephritis 
or nephrotic syndrome); (3) acute renal failure due to 
septic shock, contrast agents, or drugs; (4) postrenal dis-
ease, (5) added or changed medications except teneliglip-
tin; and (6) had missing baseline clinical or biochemical 
parameter data. The patients record was anonymized and 
de-identified prior to analysis. The daily dose of 5 mg 
linagliptin to 20 mg of teneligliptin was correspondence. 
The study protocol received ethical approval from the 
institutional review board at the Yonsei University 
College of Medicine (4–2016-0154) and Keimyung 
University School of Medicine (2017–11-034).
Clinical and Laboratory Parameters
We evaluated the effects of glucose parameters presented 
as fasting blood glucose (FBG), glycated hemoglobin 
(HbA1c), and postprandial blood glucose (PPBG) before 
and after switching from linagliptin to teneligliptin. The 
relationships between medication switching and lipid pro-
file as well as renal function were also analyzed. Estimated 
glomerular filtration rates (eGFRs) were calculated using 
the Chronic Kidney Disease Epidemiology Collaboration 
equation.13 Clinical parameters of age, sex, height, weight, 
and duration of diabetes were recorded and the body mass 
index (BMI) was calculated using the following formula: 
BMI = body weight (kg)/height (m2).
Data Analysis
The primary outcome was glycemic changes following the 
switch from linagliptin to teneligliptin. Subgroup analyses 
were stratified by baseline HbA1c (≤8.0% vs >8.0%) 
according to the American Diabetes Association (ADA) 
recommendation for older patients,14 or eGFR (≥90 mL/ 
min/1.73m2 [chronic kidney disease, CKD stage 1], 
60–89 mL/min/1.73m2 [CKD stage 2], <60 mL/min/ 
1.73m2 [CKD stage 3 or more]). Responders were defined 
as those exhibiting a ≥ 10% reduction in HbA1c values 
after 12 weeks of teneligliptin treatment.15
Statistical Analysis
The data are reported as means ± standard deviation (SD), 
and the actual numbers of participants with the percen-
tages are in parentheses. Simple comparisons of continu-
ous variables within or between sub-groups were made 
using the Student’s t-tests. Paired data measured at base-
line and after switching linagliptin to teneligliptin were 
compared using paired t-tests. Because total cholesterol, 
triglyceride, high-density lipoprotein (HDL) cholesterol, 
and low-density lipoprotein (LDL) cholesterol values 
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were not normally distributed, analyses were performed 
using log- and back-transformed data. Chi-square tests 
were used to examine the relationships between multiple 
variables. The relative factor for teneligliptin was obtained 
using multiple logistic regression and the benefit is 
reported as odds ratios (ORs) and 95% confidence inter-
vals (CIs). All statistical analyses were performed using 
the statistical package for the social sciences (SPSS) soft-
ware program (SPSS version 25.0, IBM Corp, Armonk, 




Table 1 shows the baseline clinical characteristics of 
patients and 164 (69 males and 95 females) patients were 
recruited who had a mean age of 74.5 ± 6.2 years. The 
mean duration of T2D was 16.0 ± 13.1 years and mean 
HbA1c value was 7.9 ± 1.3%. The mean eGFR was 60.7 ± 
25.0 mL/min/1.73m2 and the proportion of patients with 
CKD stage 1, 2, and >3 was 14.0%, 35.4%, and 50.6%, 
respectively. Furthermore, 70.1% of patients had hyperten-
sion that was relatively well controlled (mean systolic 
blood pressure, 129.3 ± 16.4 mmHg, mean diastolic 
blood pressure, 69.2 ± 10.6 mmHg) and 62.2% of the 
study population had a prior history of cardiovascular 
diseases. The anti-hyperglycemic drugs co-administered 
with DPP-4 inhibitors were metformin (60.4%), sulfony-
lureas (48.2%), and insulin (29.3%). More than a quarter 
of these patients were using angiotensin-converting 
enzyme inhibitors or angiotensin receptor blockers.
Effects of Switching Linagliptin to 
Teneligliptin on Hyperglycemia
The glycemic parameters of patients were significantly ame-
liorated after switching from linagliptin to teneligliptin (FBG, 
from 148.1 ± 47.1 mg/dL to 139.6 ± 43.4 mg/dL, P = 0.041; 
HbA1c, from 7.9 ± 1.3% to 7.5 ± 1.2%, P < 0.001; and PPBG, 
from 224.8 ± 77.4 mg/dL to 205.8 ± 70.8 mg/dL, P = 0.002; 
Figure 1). Less than half of the study population (42.7%) had 
difficulty in controlling T2D (baseline HbA1c ≥8.0%). Both 
uncontrolled and controlled hyperglycemia groups showed 
improvement in glycemic parameters. However, patients with 
uncontrolled hyperglycemia showed significantly better 
responses than patients with controlled T2D did (FBG, from 
160.0 ± 60.1 mg/dL to 146.5 ± 50.8 mg/dL, P = 0.085, HbA1c, 
9.1 ± 1.1% to 8.2 ± 1.3%, P < 0.001; and PPBG, from 254.8 ± 
62.8 mg/dL to 226.6 ± 71.6 mg/dL, P = 0.010; Supplementary 
Figure 1).
A total of 141 patients had impaired renal function 
(eGFR < 90 mL/min/1.73m2) and more than a half of the 
patients were diagnosed with CKD stage ≥3. 
Hyperglycemia was attenuated both in patients with nor-
mal and impaired renal function (Table 2). However, 
a significant decline in blood glucose was found only in 
Table 1 Baseline Characteristics of Study Population
Age, years 74.5 ± 6.2 (70.0–78.8)
Male sex, N (%) 69 (42.1)
Duration of type 2 diabetes, years 16.0 ± 13.1 (8.1–21.9)
Body mass index, kg/m2 25.2 ± 3.5 (23.0–27.0)
Systolic blood pressure, mmHg 129.3 ± 16.4 (119.0–140.0)
Diastolic blood pressure, mmHg 69.2 ± 10.6 (61.0–77.0)
Fasting blood glucose, mg/dl 147.8 ± 46.6 (117.0–163.0)
HbA1c, % 7.9 ±1.3 (7.1–8.5)
Postprandial blood glucose, mg/dl 225.8 ± 78.1 (167.0–276.3)
BUN, mg/dl 22.2 ± 14.2 (14.0–26.3)
Creatinine, mg/dl 1.3 ± 1.1 (0.8–1.4)
eGFR, mL/min/1.73m2 60.7 ± 25.0 (40.9–84.0)
CKD stage 1, N (%) 23 (14.0)
CKD stage 2, N (%) 58 (35.4)
CKD stage 3, N (%) 29 (17.7)
CKD stage 4, N (%) 36 (22.0)
CKD stage 5, N (%) 18 (11.0)
Albumin, mg/dL 4.2 ± 0.4 (3.9–4.4)
Total cholesterol, mg/dl 153.8 ± 36.7 (128.0–178.0)
Triglyceride, mg/dl 143.4 ± 72.6 (89.3–180.9)
HDL cholesterol, mg/dl 44.0 ± 14.1 (35.6–50.0)
LDL cholesterol, mg/dl 83.7 ± 29.6 (105.9–84.0)
AST, IU/L 25.3 ± 11.5 (18.0–29.0)
ALT, IU/L 23.6 ± 15.5 (14.0–27.0)
Comorbidities
Hypertension, N (%) 115 (70.1)






Lipid lowering agents 110 (67.1)
ACE inhibitor/ARB 72 (43.9)
CCB 56 (34.1)
Diuretics 43 (26.2)
Note: Data are presented as N (%) or mean ± SD (interquartile range). 
Abbreviations: HbA1c, glycated hemoglobin A1c; BUN, blood urea nitrogen; 
eGFR, estimated glomerular filtration rate; CKD, chronic kidney disease; HDL 
cholesterol, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cho-
lesterol; AST, aspartate transaminase; ALT, alanine transferase; SU, sulfonylurea; 
TZD, thiazolidinedione; ACE inhibitor, angiotensin-converting enzyme inhibitor; 
ARB, angiotensin II receptor blocker; CCB, calcium channel blocker.
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patients with impaired renal function. In 58 (35.4%) 
patients with CKD stage 2, FBG was decreased from 
154.9 ± 51.4 mg/dL to 137.6 ± 28.1 mg/dL (P = 0.013), 
HbA1c was decreased from 7.7 ± 1.1% to 7.2 ± 0.9% (P < 
0.001), and PPBG was decreased from 214.6 ± 85.1 mg/ 
dL to 188.3 ± 68.0 mg/dL (P = 0.019). Furthermore, 83 
(50.6%) patients with impaired renal function (CKD stage 
≥3) experienced significant decline in HbA1c (from 8.2 ± 
1.5% to 7.7 ± 0.9%, P=0.002) while 44 (26.8%) patients 
experienced >10% decline in HbA1c and were identified 
as the teneligliptin response group.
There were no significant differences in geodemographic 
parameters at baseline (Table 3). However, the teneligliptin 
response group had a higher baseline blood glucose, lower 
triglyceride level, and a higher proportion of insulin users 
than the non-response group did. Multivariable analysis 
showed that a higher baseline HbA1c was associated with a 
better response to teneligliptin (OR = 2.44, 95% CI 1.63–3.67, 
P < 0.001). However, the use of lipid-lowering agents and 
a higher triglyceride level was linked to reduced response to 
teneligliptin (OR = 0.40, 95% CI 0.17–0.97, P = 0.042 for 
lipid-lowering agent users, and OR = 0.34, 95% CI 0.14–0.82, 
P = 0.016 for triglyceride, Table 4).
Effects of Switching Linagliptin to 
Teneligliptin on Metabolic Parameters
At enrollment, 67.1% of the patients used lipid-lowering 
agents. Serum LDL cholesterol levels were significantly 
decreased from 85.6 ± 30.2 mg/dL to 78.9 ± 32.7 mg/dL 
(P = 0.004), and there were no significant changes in total 
cholesterol, triglyceride, and HDL cholesterol levels after 
switching from linagliptin to teneligliptin. The renal func-
tion and liver enzymes were conserved (Table 5).
Discussion
The major finding of this study is that switching from 
linagliptin to teneligliptin may facilitate the control of 
hyperglycemia in older patients with T2D. Specifically, 
A B C
Figure 1 Changes in glycemic parameters after switching to teneligliptin. (A) Fasting blood glucose, (B) postprandial blood glucose, and (C) glycated hemoglobin A1c 
(HbA1c). Red line indicates trend line.
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Table 2 Changes in Glycemic Parameters by Chronic Kidney Disease Stages
Parameters Before Switching After Switching Δ P value
CKD stage 1 (N=23)
Fasting blood glucose, mg/dl 131.0 ± 26.2 138.3 ± 36.9 7.3 ± 48.6 0.482
HbA1c, % 7.7 ± 0.8 7.5 ± 0.9 −0.2 ± 0.8 0.244
Postprandial blood glucose, mg/dl 225.2 ± 83.6 203.2 ± 66.4 −22.0 ± 68.2 0.156
CKD stage 2 (N=58)
Fasting blood glucose, mg/dl 154.9 ± 51.4 137.6 ± 38.1 −17.3 ± 50.0 0.013
HbA1c, % 7.7 ± 1.1 7.3 ± 0.9 −0.5 ± 0.7 <0.001
Postprandial blood glucose, mg/dl 214.6 ± 85.1 188.3 ± 68.0 −26.2 ± 77.4 0.019
CKD stage 3- (N=83)
Fasting blood glucose, mg/dl 147.8 ± 47.5 141.3 ± 48.4 −6.6 ± 53.6 0.275
HbA1c, % 8.2 ± 1.5 7.7 ± 1.4 −0.4 ± 1.2 0.002
Postprandial blood glucose, mg/dl 231.8 ± 70.0 218.8 ± 72.0 −13.0 ± 72.4 0.129
Note: Data are presented as N (%) or mean ± SD. 
Abbreviations: HbA1c, glycated hemoglobin A1c; CKD, chronic kidney disease.
Table 3 Comparison of Response to Teneligliptin Switching
Non-Responder (N=120) Responder (N=44) P value
Age, years 74.4 ± 6.1 74.9 ± 6.6 0.627
Male sex, N (%) 46 (38.3) 23 (52.3) 0.109
Duration of type 2 diabetes, years 15.3 ± 13.7 18.0 ± 11.1 0.245
Body mass index, kg/m2 25.3 ± 3.6 25.0 ± 3.1 0.661
Fasting blood glucose, mg/dl, baseline 142.9 ± 41.0 160.8 ± 57.5 0.064
Fasting blood glucose, mg/dl, after switching 141.2 ± 37.9 135.0 ± 56.0** 0.428
HbA1c, %, baseline 7.6 ± 1.1 8.9 ± 1.4 <0.001
HbA1c, %, after switching 7.6 ± 1.3 7.3 ± 1.0** 0.118
Postprandial blood glucose, mg/dl, baseline 220.3 ± 76.2 240.3 ± 82.2 0.163
Postprandial blood glucose, mg/dl, after switching 199.2 ± 68.0** 222.8 ± 74.7 0.089
eGFR, mL/min/1.73m2, baseline 64.7 ± 24.5 59.4 ± 29.1 0.173
eGFR, mL/min/1.73m2, after switching 60.1 ± 22.2 54.4 ± 28.8 0.242
Total cholesterol, mg/dl, baseline* 161.2 ± 39.0 145.5 ± 30.5 0.122
Total cholesterol, mg/dl, after switching* 152.8 ± 37.0** 152.6 ± 48.9 0.696
Triglyceride, mg/dl, baseline* 159.0 ± 75.3 120.8 ± 61.5 0.007
Triglyceride, mg/dl, after switching* 154.7 ± 74.0 126.7 ± 53.3 0.017
HDL cholesterol, mg/dl, baseline* 43.0 ± 10.9 45.6 ± 17.1 0.789
HDL cholesterol, mg/dl, after switching* 42.7 ± 10.0 46.3 ± 20.1 0.672
LDL cholesterol, mg/dl, baseline* 87.4 ± 32.6 80.6 ± 23.1 0.740
LDL cholesterol, mg/dl, after switching* 78.4 ± 31.3** 80.4 ± 36.5 0.914
Medications, N (%)
Metformin 77 (64.2) 22 (50.0) 0.100
SU 54 (45.0) 25 (56.8) 0.180
TZD 6 (5.0) 4 (9.1) 0.332
Insulin 30 (25.0) 18 (40.9) 0.047
Statin 85 (70.8) 25 (56.8) 0.091
Notes: Data are presented as N (%) or mean ± SD. *Log transformed. **P<0.05 compared with baseline. 
Abbreviations: HbA1c, glycated hemoglobin A1c; BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate; CKD, chronic kidney disease; HDL cholesterol, 
high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; AST, aspartate transaminase; ALT, alanine transferase; SU, sulfonylurea; TZD, thiazolidine-
dione; ACE inhibitor, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker.
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switching to teneligliptin reduced hyperglycemia in 
patients with impaired renal function while maintaining 
their eGFR, indicating the renoprotective effect of teneli-
gliptin. In addition, the effects were greater in patients 
with uncontrolled than in those with controlled hypergly-
cemia independent of other contributing factors including 
age, sex, duration of T2D, and insulin use. Guidelines of 
both the Korean Diabetes Association and ADA recom-
mend the combination or supplementation of other classes 
of anti-hyperglycemic agents to achieve glycemic 
targets.16,17 In addition to achieving the glycemic goal, 
maintaining glucose levels without inducing hypoglycemia 
is important and, therefore, guidelines emphasize an indi-
vidualized glycemic target considering life expectancy, 
complications of T2D, and advanced age.
Those factors are more prevalent in the older population 
and older patients are more vulnerable to hypoglycemia.18 In 
addition, an increase in the number of medications reduces 
patient adherence and supplementation with other 
hypoglycemic agent increases the possibility of drug inter-
actions and side effects as well as medical costs. 
Consequently, switching agents from the same class of anti- 
hyperglycemic agents would be a reasonable and relatively 
safe strategy, and would provide an alternative therapeutic 
option. In this study, we provide clinical evidence to show 
that switching agents in the same drug class could be a viable 
option before considering adding drugs from other classes. 
Moreover, our data showed a more potent glucose-lowering 
effect in patients with uncontrolled hyperglycemia than in 
those with controlled hyperglycemia.
The difference in binding site and affinity of the receptor 
site is possibly associated with the efficacy of switching 
from linagliptin to teneligliptin in blood glucose control. 
DPP-4 inhibitors are categorized according to their binding 
site and teneligliptin is classified as a class 3 agent, whereas 
linagliptin is characterized as class 2.19 Teneligliptin has 
a unique J-shape structure formed by five rings directly 
connected and the loss of entropy is small at the binding 
site. Teneligliptin is a peptide mimetic and the carbonyl 
group forms a hydrogen bond at the binding site, strength-
ening the binding interaction.20 In addition, the anchor lock 
domain ([1-phenylpyrazol-5-yl] piperazine moiety) makes 
teneligliptin to bind more tightly to the DPP-4 enzyme than 
other gliptins ands well as enhances the selectivity of the 
binding.20 The long endurance and strong binding affinity 
of teneligliptin to the DPP-4 enzyme makes it more potent, 
and it further decreases blood glucose levels when patients 
switched to this agent. Teneligliptin, which is also a class 3 
DPP-4 inhibitor, increased activated GLP-1 levels more 
than sitagliptin did, as reported in a Japanese pilot study.21 
Moreover, recent studies demonstrated that teneligliptin 
rescues endothelial cell viability through the ERK5/KLF2 
signaling pathway.22,23 However, it would still be necessary 
to investigate whether the differences in binding modes 
Table 5 Changes in Metabolic Parameters After Switching to Teneligliptin
Parameters Baseline After Switching Δ P value
eGFR, mL/min/1.73m2 60.1 ± 24.9 58.6 ± 24.1 −1.5 ± 11.7 0.109
Total cholesterol, mg/dL* 156.9 ± 37.4 152.7 ± 40.5 −4.2 ± 41.8 0.128
Triglycerides, mg/dL* 148.8 ± 73.7 147.3 ± 70.0 −1.5 ± 62.1 0.837
HDL cholesterol, mg/dl* 43.7 ± 12.8 43.7 ± 13.5 0.1 ± 13.1 0.951
LDL cholesterol, mg/dl* 85.6± 30.2 78.9 ± 32.7 −6.6 ± 34.3 0.004
AST, IU/L* 25.4 ± 11.6 25.5 ±13.9 0.1 ± 11.8 0.475
ALT, IU/L* 23.7 ± 15.7 22.1 ± 14.6 −1.6 ± 12.9 0.065
Notes: Data are presented mean ± SD. *log-transformed. 
Abbreviations: eGFR, estimated glomerular filtration rate; HDL cholesterol, high-density lipoprotein cholesterol, LDL cholesterol; low-density lipoprotein cholesterol; 
AST, aspartate transaminase; ALT, alanine transferase.
Table 4 Multiple Regression Analysis to Determine Variables 
Associated Responders of Switching to Teneligliptin
OR 95% CI P value
Age, year 1.00 0.93–1.07 0.947
Sex, male 1.10 0.46–2.62 0.832
Body mass index, kg/m2 0.99 0.87–1.13 0.927
Duration of type 2 diabetes, year 0.88 0.97–1.03 0.880
Baseline HbA1c, % 2.44 1.62–3.67 <0.001
Triglyceride, baseline, mg/dl* 0.34 0.14–0.82 0.016
LDL cholesterol, mg/dl* 0.95 0.30–3.10 0.954
CKD stage 3 or more 0.97 0.41–2.59 0.929
Lipid lowering agent use 0.40 0.17–0.97 0.042
Insulin use 0.99 0.34–2.99 0.989
Note: *log-transformed. 
Abbreviations: OR, odds ratio; 95% CI, 95% confidence interval; HbA1c, glycated 
hemoglobin A1c; LDL cholesterol, low-density lipoprotein cholesterol; CKD, 
chronic kidney disease.
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between teneligliptin and other DPP-4 inhibitors are clini-
cally meaningful.
In glycemic control, DPP-4 inhibitors generally 
decrease HbA1c levels (0.5–1.0%) and the efficacy 
among DPP-4 inhibitors is similar.4,24–26 However, the 
effect of switching between DPP-4 inhibitors has been 
scantly studied and studies have reported conflicting 
results according to the type of DPP-4 inhibitor. 
A retrospective study conducted in the UK demonstrated 
that the changes in HbA1c after switching to alogliptin 
were insignificant.27 However, a recent prospective study 
showed a positive result in switching to teneligliptin.28 
The additional 0.4% reduction in HbA1c levels observed 
in the present study was comparable to that previously 
reported,28 although the baseline characteristics of the 
patients were different from those of our study. Our results 
showed that the effect of switching to teneligliptin was 
favorable in older patients with impaired renal function 
and long T2D duration, suggesting the efficacy was com-
parable to that in a younger population and those with 
normal kidney function. More head-to-head, comparative 
trials are needed to confirm the glycemic efficacy in chan-
ging DPP-4 inhibitors.
In addition to glucose-lowering effects, numerous studies 
have suggested that DPP-4 inhibitors have a pleiotropic 
effect on other organs including the kidney and blood 
vessels.29–31 The potential protective effects or inhibitory 
actions of these agents against the progression of diabetic 
kidney disease are mediated through anti-inflammatory, anti-
oxidative, and anti-fibrotic activities.31–34 Among DPP4 
inhibitors, the renoprotective effect of linagliptin has been 
well studied and dose reduction is not required in patients 
with CKD.33–35 Both teneligliptin and linagliptin have higher 
lipophilicity and greater distribution in the kidney than that of 
other DPP4 inhibitors.36 Additionally, a pilot study showed 
a more significant reduction in DPP-4 activity of both tene-
ligliptin and linagliptin than that of other DPP-4 inhibitors, 
and failed to demonstrate any distinction between teneliglip-
tin and linagliptin.37 Our results did not show any statistical 
significance in changes of eGFR after patients switched to 
teneligliptin; however, a significant reduction in HbA1c 
occurred only in patients with impaired renal function. This 
observation suggests the comparable renoprotective effect of 
linagliptin, indicating that switching to teneligliptin might be 
beneficial for T2D patients with CKD.
Our results are in accordance with a previous meta- 
analysis showing that baseline HbA1c is the strongest 
predictor of responses to DPP-4 inhibitors.24,25 However, 
we unexpectedly discovered the lipid-lowering use and 
found that higher triglyceride concentrations are associated 
with a lower response following switching to teneligliptin. 
Although we did not find any association between teneli-
gliptin response and BMI, other studies showed that an 
insulin-resistant state could reduce responses to DPP-4 
inhibitors. In a cohort study in the UK, obesity (≥30 kg/ 
m2 BMI) and increased triglyceride markedly reduced 
glycemic response and durability of DPP-4 inhibitor 
therapy.38 A Japanese study reported similar results that 
the average triglyceride level was an independent factor 
contributing to the efficacy of DPP-4 inhibitor in obese 
patients.39 Lipotoxicity disrupts cell-to-cell communica-
tion in incretin-sensitive beta cells, impairing GLP-1 
response, thus, altering insulin secretion.40 In addition, 
fatty acid mediates downregulation of the expression of 
connexin 36, an integral membrane protein cluster at gap 
junction domains of beta-cell membranes.41 The experi-
mental data suggest that alterations of this signaling impair 
beta-cells connectivity.
Our study has a few limitations that are worth mention-
ing. First, because it was a retrospective investigation, 
some confounders might have influenced glycemic control 
other than anti-hyperglycemic medications. Although the 
patients were prescribed the same number of medications, 
they exhibited hyperglycemia; thus, there might be some 
attempt to improve this condition. Second, we did not 
include a control group. Further head-to-head studies are 
needed to elucidate the difference in glycemic control 
among DPP-4 inhibitors. Additionally, we did not investi-
gate the outcome of switching from teneligliptin to lina-
gliptin. Third, medication compliance was not fully 
considered in the present study. Because this was not 
a prospective study, we could not assess adherence to 
prescribed medications. The study data were based on 
the proposition that all the prescribed medications were 
administered to the patients.
In conclusion, our findings demonstrate that switch-
ing from linagliptin to teneligliptin in older patients with 
T2D ameliorated blood glucose levels and preserved 
kidney function. This suggests that switching DPP-4 
inhibitors, especially to teneligliptin, could be 
a therapeutic option to control hyperglycemia in diffi-
cult-to-treat T2D. However, further randomized trials 
are needed to quantify this beneficial effect in switching 
to teneligliptin compared to other DPP4 inhibitors and 
control groups.
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